MMRF launches MyDRUG multiple myeloma platform trial

The Multiple Myeloma Research Foundation launched the collaborative MyDRUG platform trial to identify new treatment options for molecularly defined subgroups of patients. The Phase I/II signal-finding study builds upon the patient group's 2011 CoMMpass trial, which was designed to identify molecular drivers of MM.

MMRF said MyDRUG is the first platform trial exclusively in multiple myeloma. MyDRUG will contain at least five arms defined by molecular signature and patients who harbor those signatures will then receive a specific targeted agent that has shown activity in that pathway...